课题基金 / 基金详情

Dual – action antiviral dyes to support the fight against COVID-19

Dual – action antiviral dyes to support the fight against COVID-19
双效抗病毒染料支持抗击 COVID-19
批准号:
74915
负责人:
金额:
$46.55万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
Colorifix率先在不同类型的织物上生产、沉积和固定天然色素,并从外部验证了它们对医院环境中常见病原体的抗菌性能。其中一些色素还具有抗病毒活性。利用这笔赠款的支持,我们的目标是生产安全、可持续和有效的新一代天然抗病毒染料,以支持抗击COVID-19。Colorifix将与剑桥大学的两个领先研究小组合作,他们在病毒学、纳米材料和光触发化学方面拥有专业知识,这将有助于在抗病毒染料设计的利基领域建立新的研发平台,具有巨大的知识产权生成潜力。为了实现我们的目标,我们将确定最好的天然抗病毒色素候选物,然后利用我们在合成生物学方面的专业知识在安全的工业微生物中生产。抗病毒色素将与Colorifix先前开发并经过外部验证的抗菌染料相结合,创造出具有双重抗病毒/抗菌作用的独特色素配方。我们的染料与织物永久结合,提供耐用、持久和安全(不浸出)的抗COVID - 19织物,可能有效中和导致呼吸系统疾病的其他常见病毒和细菌,这是导致严重感染COVID患者数量的主要合并症因素。与其他表面配方不同,我们的抗病毒面料不以物理去除病毒为目标,而是通过在黑暗和暴露在阳光或紫外线下的双重作用模式完全灭活。因此,可以大大降低病毒的传播率。利用我们的专利技术,生产色素的微生物将用于从医疗保健(PPE)到一般服装、包装或公共交通部门的织物染色。除了对预防感染的影响外,Colorifix的专利方法还显著减少了生产过程中化学品和水的使用,从而对环境产生了重大影响,这也影响了总体成本。我们将与外部学术和工业合作伙伴合作,验证新染料的抗病毒潜力,并确保它们符合安全标准。Colorifix与国际时尚品牌、工厂和染坊建立了牢固的关系,其中包括获得转基因许可的欧洲生产基地,这意味着该产品可以迅速扩大规模,并融入现有的制造链,为进入市场提供了一条快速途径。
英文摘要
Colorifix has pioneered the production, deposition and fixation of natural pigments on diverse types of fabrics and externally validated their antimicrobial properties against pathogens common in hospital settings. Some of these pigments are also known to possess antiviral activity. Using the support from this grant, we aim to produce the next-generation of safe, sustainable and effective natural antiviral dyes to support the fight against COVID-19\. Colorifix will team up with two leading research groups from the University of Cambridge, with expertise in virology, nanomaterials and photo triggered chemistry, which will help establish new R&D platforms in a niche area of antiviral dye design, with a significant potential for IP generation. To achieve our goals we will identify the best natural antiviral pigment candidates that will then be produced in a safe industrial microorganism using our expertise in synthetic biology. Antiviral pigments will be combined with antimicrobial dyes previously developed by Colorifix and externally validated to create a unique pigment formulation with dual antiviral/antimicrobial action. Our dyes are permanently bound to fabric, offering durable, long-lasting and safe (non-leaching) anti-COVID19 fabric, with potential effective neutralisation of other common viruses and bacteria responsible for respiratory conditions, a major comorbidity factor which contributes to the number of severely affected COVID patients. Unlike other surface formulations, our antiviral fabrics do not aim at the physical removal of the virus, but complete deactivation through dual mode of action both in dark and on exposure to sun or ultraviolet light. As a consequence, dramatic reduction of transmission rates of the virus can be achieved. Harnessing our patented technology, pigment-producing microorganisms will be used to dye fabrics with application from healthcare (PPE), to general clothing, packaging or public transport sectors. Besides the impact on infection prevention, Colorifix's patented approach has a substantial environmental impact by significantly reducing the use of chemicals and water in the manufacturing process, which also impacts the overall cost. We will collaborate with external academic and industrial partners to validate the antiviral potential of the new dyes and to ensure they meet safety standards. Colorifix has strong relationships with international fashion brands, mills and dye houses, including GM-licensed European production sites, which means the product can be scaled up quickly and integrated into existing manufacturing chains offering a rapid route to market.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
  • 批准号:
    82371028
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵慧
  • 依托单位:
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
  • 批准号:
    82372743
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈卓佳
  • 依托单位:
空气颗粒物通过调控白血病抑制因子参与影响IgA肾病进展的作用与机制研究
  • 批准号:
    82370711
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    谢静远
  • 依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
  • 批准号:
    82371054
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郭涛
  • 依托单位: